Pathologic Myopia
📧 Sign up to get email alerts when something new happens for Pathologic Myopia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-09EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia [NA]
A study is underway to test LED red light therapy to modulate choroidal microcirculation and retard retinal atrophy in pathological myopia. …
-
EMA approval · 2025-12-17EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited
EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, dia…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: High-throughput Large-model-based AI-assisted Diagnosis Using OCT
A clinical trial update for a high-throughput AI system using OCT for retinal disease diagnosis; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: Follow up of High Myopic Eyes
A clinical trial update notes that a study on follow-up of high myopic eyes with pathologic myopia is currently recruiting, sponsored by Ist…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses [NA]
A prospective randomized clinical trial comparing two phakic toric intraocular lenses for myopia with astigmatism is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2017-07-28Clinical Trial Update: Ocular Discomfort Assessment After Intravitreal Injections [NA]
This completed clinical trial update reports measurements of ocular discomfort after intravitreal injections. The findings may inform the sa…
-
FDA approval · 2014-05-06FDA Approved: VISUDYNE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for VISUDYNE (verteporfin for injection) filed by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2014-04-01Clinical Trial Update: VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) [Phase 3]
Phase 3 trial evaluating VEGF Trap-Eye for choroidal neovascularization due to pathologic myopia has completed, with results posted in 2014.…
-
CLINICAL_TRIALS trial_result · 2013-10-28Clinical Trial Update: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia [Phase 1]
Phase 1 trial evaluating reduced-fluence verteporfin photodynamic therapy in combination with ranibizumab for choroidal neovascularization i…
-
FDA approval · 2013-10-08FDA Approved: VISUDYNE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Visudyne (verteporfin for injection) filed by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS research · 2012-10-25Clinical Trial Update: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy [Phase 1, Phase 2]
Phase 1/2 clinical trial update on treatments for exudative and vasogenic chorioretinal diseases including AMD variants and other CNV-relate…
-
CLINICAL_TRIALS trial_result · 2011-11-01Clinical Trial Update: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 2]
Phase 2 trial assessing safety and efficacy of Combretastatin A4 Phosphate for choroidal neovascularization secondary to pathologic myopia h…